News

EVI-supported project publishes first clinical results for vaccine candidate to prevent pregnancy-associated malaria.

European Commission highlights that EU-funded TRANSVAC2 project is developing infrastructure to support innovation and accelerate the development of new vaccines and thereby will enhance European competitiveness in this field and bring major societal benefits.

Deadline for submission: 7 March 2019, 16:00 (GMT)

Meeting report summarising the outcome of the EDUFLUVAC workshop on “Experimental animal models for universal influenza vaccines” has been published in Vaccine

EVI is seeking a visionary Executive Director (ED) with a track record in health product development and mobilizing resources for innovative programmes.

New call launched on 15 October.

Second call for training modules now open

We are pleased to share with you the EVI Annual Report 2017. You can download or view it using the following link. We hope you have an interesting read.

New article published on 17 July 2018 in npj  Vaccines: “Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development”.

On 20/21 November, EVI will celebrate its 20th anniversary with a symposium in Heidelberg, Germany. A draft agenda is now available.

If you are interested in attending in the symposium please fill in the application form using the following LINK. We will contact you in due course.

See attached document for more information surrounding the symposium.